Advancements in Hidradenitis Suppurativa Therapies as Per DelveInsight Report
News related to:DelveInsight · 3 min read
DelveInsight, a market research firm, has released a comprehensive report on the Hidradenitis Suppurativa pipeline outlook for 2026, highlighting the advancements in oral, injectable, and novel delivery candidates.
The report covers a wide range of pipeline products, from pre-clinical development to marketed phases, offering detailed insights into the drug's mechanism of action, clinical studies, NDA approvals, and product development activities. Key companies involved in the development of therapies for Hidradenitis Suppurativa include Kymera Therapeutics, CSL Behring, Azora Therapeutics, Union Therapeutics, Eli Lilly and Company, Boehringer Ingelheim, ACELYRIN, Incyte Corporation, InflaRx, Novartis, ChemoCentryx, Janssen Pharmaceutical/XBiotech, Aclaris Therapeutics, and others.
Among the emerging therapies in various phases of clinical trials are KT-474 from Kymera Therapeutics, CSL324 from CSL Behring, AT193 from Azora Therapeutics, Orismilast from Union Therapeutics, LY3041658 from Eli Lilly and Company, Spesolimab from Boehringer Ingelheim, Izokibep from ACELYRIN, INCB054707 from Incyte Corporation, IFX-1 from InflaRx, Cosentyx/Secukinumab from Novartis, Avacopan from ChemoCentryx, Bermekimab from Janssen Pharmaceutical/XBiotech, and Zunsemetinib (ATI-450) from Aclaris Therapeutics. These therapies are expected to significantly impact the Hidradenitis Suppurativa market in the coming years.
In November 2026, Zura Bio announced that its Phase II TibuSHIELD trial evaluating tibulizumab (ZB-106), a dual IL-17A and BAFF inhibitor, failed to meet its primary endpoint of reducing abscess and inflammatory nodule counts at Week 16. The study also failed to achieve key secondary endpoints, including HiSCR50 and HiSCR75. Following the results, the company decided to discontinue tibulizumab development for hidradenitis suppurativa.
In October 2026, AbbVie announced positive topline results from its Phase III INTREPID trial evaluating lutikizumab, an investigational dual IL-1α/IL-1β inhibitor, in adults and adolescents with moderate-to-severe hidradenitis suppurativa. The study achieved its primary endpoint, with 31.4% of patients receiving lutikizumab achieving HiSCR75 at Week 16 compared with 23.4% in the placebo group. The treatment also demonstrated improvements in HS-related skin pain and reductions in disease flares. AbbVie plans to use the findings to support regulatory submissions in the second half of 2027.
In September 2026, Corvus Pharmaceuticals initiated a Phase Ib clinical trial evaluating soquelitinib in patients with hidradenitis suppurativa. The study is designed to assess the drug's safety, efficacy, and ability to modulate Th17-driven inflammatory pathways. This clinical development program aims to explore the potential of soquelitinib as a novel treatment option for patients with HS.
In July 2026, the results of the Phase III STOP-HS1 and STOP-HS2 trials evaluating povorcitinib, an oral selective JAK1 inhibitor, were published in Nature Medicine. The studies investigated its efficacy and safety in patients with moderate-to-severe hidradenitis suppurativa. The publication provided clinical evidence supporting povorcitinib's potential as an oral treatment option and its subsequent European regulatory approval.
In March 2026, Novartis strengthened its dermatology portfolio amid ongoing FDA-supported progress for IL-17A biologic therapies, including Cosentyx (secukinumab), further solidifying its position in the expanding biologics-based treatment landscape for moderate-to-severe hidradenitis suppurativa cases.
In February 2026, Novartis Japan expanded clinical positioning of secukinumab (Cosentyx) following global FDA approvals, strengthening biologic treatment adoption for inflammatory skin disorders including hidradenitis suppurativa.
In January 2026, MoonLake Immunotherapeutics advanced its regulatory engagement with the FDA regarding sonelokimab, an investigational therapy targeting IL-17A/F pathways, highlighting its potential role in the development of next-generation biologic treatments for hidradenitis suppurativa.
In January 2026, Mitsubishi Tanabe Pharma Corporation, part of the Mitsubishi Chemical Group, intensified its dermatology-centered R&D initiatives focused on autoimmune and inflammatory skin disorders, further advancing its pipeline expansion in biologics and immunomodulatory therapies.
In December 2025, UCB Pharma Japan enhanced its commercialization strategies for advanced biologic therapies targeting chronic inflammatory skin disorders, utilizing IL-focused treatments to improve outcomes for patients with moderate-to-severe hidradenitis suppurativa.
In September 2025, UCB shared three-year results from the BE HEARD trials evaluating BIMZELX® (bimekizumab-bkzx) in adults with moderate-to-severe hidradenitis suppurativa.